Given the prolonged survival in patients with (especially human epidermal growth factor receptor 2‐postive, HER2+) breast cancer and NSCLC with epidermal growth factor receptor (EGFR) mutations and anaplastic large‐cell lymphoma kinase (ALK) rearrangements over the past years due to improvements in targeted therapies, the treatment of hydrocephalus associated with LMD through CSF drainage via VPS has experienced an increasing relevance.25, 26, 27, 28. The gene discussed is ERBB2; the disease is Hydrocephalus.